The board of directors of Sinopharm Group Co. Ltd. announced that, the Company has reached the strategic cooperation with TSB Therapeutics (Beijing) Co. Ltd. Both parties will work together to promote the commercial progress of COVID-19 monoclonal neutralizing antibody therapy, the amubarvimab/romlusevimab combination (previously known as BRII-196/BRII-198 combination), in the PRC, including drug stockpiling, channel distribution, hospital access and other innovative business cooperation, so as to support the prevention and control of COVID-19 pandemic together.

The amubarvimab/romlusevimab combination has been approved by the National Medical Products Administration (NMPA) for listing on 8 December 2021, and approved by the National Health Commission to be included in the "COVID-19 Diagnosis and Treatment Guidelines (9th pilot Edition)" on 15 March 2022. As approved by national competent health administrative authorities and clinical specialists for the amubarvimab/romlusevimab combination, as of 29 March 2022, Brii Biosciences has successively received procurement intention and stockpiling demand from local competent health administrative authorities and hundreds of medical institutions and commercial units in the PRC. Brii Biosciences is speeding up the preparation of medicine production and supply, dedicating to benefiting patients with drug therapy as soon as practicable.